ஈட்டி மருந்துகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஈட்டி மருந்துகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஈட்டி மருந்துகள் Today - Breaking & Trending Today

Seelos Therapeutics Doses First Patient in Part 2 of a Registrational Study of SLS-002 for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

Seelos Therapeutics Doses First Patient in Part 2 of a Registrational Study of SLS-002 for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.

New York , United States , Anthony Marciano , Centers For Disease , Emergency Department , Javelin Pharmaceuticals Inc Hospira , Seelos Therapeutics Inc , Exchange Commission , Head Of Corporate Communications , Agency For Healthcare Research , Seelos Therapeutics , Acute Suicidal Ideation , Major Depressive Disorder , Disease Control , Post Traumatic Stress , Javelin Pharmaceuticals , Healthcare Research , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Corporate Communications , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , அந்தோணி மார்சியானோ , மையங்கள் க்கு நோய் , அவசரம் துறை ,

Seelos Therapeutics Announces its Inclusion in the First U.S. Listed Exchange Traded Fund (ETF) Focused on Psychedelics

/PRNewswire/ Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central. ....

New York , United States , New York Stock Exchange , Anthony Marciano , York Stock Exchange , Javelin Pharmaceuticals Inc Hospira , Prnewswire Seelos Therapeutics Inc , Seelos Therapeutics Inc , Exchange Traded Fund , Exchange Commission , Defiance Etfs , Head Of Corporate Communications , Agency For Healthcare Research , National Suicide Prevention Lifeline , Defiance Next Gen Altered Experience , Acute Suicidal Ideation , Major Depressive Disorder , Ketamine Index , North American Exchanges , Medical Cannabis , Post Traumatic Stress Disorder , Javelin Pharmaceuticals , Healthcare Research , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports ,

Seelos Therapeutics Announces Completion of Open-Label Patient Enrollment of Proof of Concept Study of SLS-002 for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the completion of enrollment of patients in Part 1 of its registrational Proof of Concept study of SLS-002 for Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder . Seelos expects to release key open-label data …
– Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the completion of enrollment of patients in Part 1 of its registrational Proof of Concept study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD). ....

New York , United States , Anthony Marciano , Exchange Commission , Javelin Pharmaceuticals Inc Hospira , Seelos Therapeutics Inc , Head Of Corporate Communications , Agency For Healthcare Research , National Suicide Prevention Lifeline , Seelos Therapeutics , Acute Suicidal Ideation , Major Depressive Disorder , Post Traumatic Stress , Javelin Pharmaceuticals , Healthcare Research , Post Traumatic Stress Disorder , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Corporate Communications , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , அந்தோணி மார்சியானோ , பரிமாற்றம் தரகு , சீலோஸ் சிகிச்சை இன்க் , தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் ,

Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program)

Share this article
Share this article
NEW YORK, Feb. 18, 2021 /PRNewswire/ Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today an amendment of the agreement with Vyera Pharmaceuticals AG ( Vyera ) for the development of SLS-002 (intranasal racemic ketamine) to repurchase in cash a significant portion of the royalties payable on any future net sales of SLS-002.
On March 6, 2018, Seelos entered into an asset purchase agreement with Vyera, currently known as Phoenixus AG, to acquire the assets and liabilities of Vyera s intranasal racemic ketamine program, which Seelos now calls SLS-002. As additional consideration to certain upfront cash and equity payments and success-based milestone payments contemplated under the prior agreement, Seelos agreed to pay a mid-teens percentage royalty on any future net sales of SLS-002. Under ....

New York , United States , Anthony Marciano , Javelin Pharmaceuticals Inc Hospira , Prnewswire Seelos Therapeutics Inc , Seelos Therapeutics Inc , Vyera Pharmaceuticals Ag , Exchange Commission , Head Of Corporate Communications , National Suicide Prevention Lifeline , Agency For Healthcare Research , Vyera Pharmaceuticals , Acute Suicidal Ideation , Major Depressive Disorder , Post Traumatic Stress , Javelin Pharmaceuticals , Healthcare Research , Post Traumatic Stress Disorder , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Seelos Therapeutics , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , அந்தோணி மார்சியானோ , சீலோஸ் சிகிச்சை இன்க் ,

Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002

Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today an amendment of the agreement with Vyera Pharmaceuticals AG for the development of SLS-002 to repurchase in cash a significant portion of the royalties payable on any future net sales of SLS-002. On March 6, 2018 Seelos entered into an . ....

New York , United States , Anthony Marciano , Javelin Pharmaceuticals Inc Hospira , Seelos Therapeutics Inc , Vyera Pharmaceuticals Ag , Exchange Commission , Head Of Corporate Communications , National Suicide Prevention Lifeline , Agency For Healthcare Research , Seelos Therapeutics , Vyera Pharmaceuticals , Acute Suicidal Ideation , Major Depressive Disorder , Post Traumatic Stress , Javelin Pharmaceuticals , Healthcare Research , Post Traumatic Stress Disorder , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Corporate Communications , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , அந்தோணி மார்சியானோ , சீலோஸ் சிகிச்சை இன்க் ,